Core Viewpoint - *ST WanFang (000638) is expected to face financial difficulties in 2025, with projected operating revenue below 300 million yuan and potential negative profit figures, which may lead to delisting from the Shenzhen Stock Exchange due to financial criteria violations [1][2] Financial Performance - The company anticipates that its operating revenue for 2025 will be less than 300 million yuan [1] - There is a risk that the total profit, net profit, or net profit after deducting non-recurring gains and losses will be negative for the same year [1] Audit Report Concerns - Zhongxing Caiguanghua Accounting Firm issued a qualified audit report for the company's 2024 financial statements, highlighting uncertainties regarding the recoverability of investments in Jilin WanFang Baiao Biotechnology Co., Ltd [1] - As of the announcement date, the uncertainty regarding the company's financial situation has not been resolved, and there remains a risk of receiving a qualified audit report for 2025 [2] Delisting Risk - If the company receives a qualified audit report for 2025, it may trigger delisting warnings and ultimately lead to termination of stock trading under the Shenzhen Stock Exchange rules [2]

Core Viewpoint - *ST Yanshi (Shanghai Gui Jiu) is expected to face financial delisting due to projected revenue below 300 million yuan and negative net profits for the fiscal year 2025 [1][9]. Financial Performance - The company reported revenue of 34.76 million yuan for the first three quarters of 2025, with a net profit of approximately -112 million yuan [5][13]. - The stock price plummeted to 3.04 yuan per share, a decline of over 80% from its historical high of 51.66 yuan [3][11]. Regulatory Context - According to exchange regulations, if the audited revenue for 2025 is below 300 million yuan and either total profit or net profit (after excluding non-recurring gains and losses) is negative, the stock will be delisted [5][13]. Company Background - The actual controller of Shanghai Gui Jiu, Han Xiao, is linked to Han Hongwei, the actual controller of Haiyin Wealth, which faced a financial crisis due to illegal fundraising activities [6][14]. - The company has been under scrutiny since April 2024 for false reporting in annual reports from 2017 to 2020, leading to public condemnation and legal actions against its executives [6][14]. Market Activity - Despite the impending delisting, some investors continue to trade the stock, with a cumulative price deviation of 12% over three consecutive trading days [14]. - The company has initiated aggressive discount sales through live-streaming, with products previously priced at 1,819 yuan now available for as low as 200 yuan [14].

Core Viewpoint - *ST岩石 is facing a potential delisting warning due to projected financial difficulties, with expected revenue for 2025 falling below 300 million yuan and negative profit figures [1][4]. Financial Performance - For the first three quarters of 2025, *ST岩石 reported cumulative revenue of 34.76 million yuan and a net profit attributable to shareholders of -112 million yuan [4]. - In 2021, the company achieved revenue of 603 million yuan and a net profit of 61.93 million yuan, while in 2022, revenue exceeded 1 billion yuan [4]. - The company experienced significant growth in 2023, with revenue surpassing 1.6 billion yuan and a net profit exceeding 87 million yuan [4]. - However, in 2024, revenue drastically declined to 285 million yuan due to a drop in white liquor sales [4]. Audit and Compliance Issues - The 2024 financial report received a qualified opinion from the auditing firm, citing major uncertainties regarding the company's ability to continue as a going concern [5]. - The audit report highlighted issues such as significant declines in revenue, negative operating cash flow, and a current ratio indicating that current liabilities exceed current assets [5]. - The company is currently undergoing an audit process, and the resolution of the issues raised in the qualified opinion remains uncertain [5][6]. Management and Operational Challenges - The company has faced operational challenges, including staff reductions and halted production and construction activities due to financial constraints [5]. - The actual controller of *ST岩石, 韩啸, has been subjected to criminal measures due to allegations of illegal fundraising related to 海银财富管理有限公司 [6]. Market Reaction - Despite the looming delisting warning and operational issues, *ST岩石's stock experienced a limit-up on January 12, with a market capitalization of approximately 1.1 billion yuan [6].

Core Viewpoint - *ST Rock (600696) has announced a projected loss for the fiscal year 2025, which may lead to the termination of its stock listing due to financial criteria [2][4]. Group 1: Financial Performance - The company anticipates that its operating revenue for 2025 will be below 300 million yuan, with either total profit, net profit, or net profit after deducting non-recurring gains and losses expected to be negative [2]. - The 2024 financial report received a qualified audit opinion from Zhongxing Caiguanghua Accounting Firm, indicating significant uncertainties regarding the company's ability to continue as a going concern [4]. Group 2: Stock Listing Risks - If the 2025 financial report receives a qualified opinion, or if there are negative opinions on internal controls, the company's stock may be delisted due to financial criteria [4]. - The company's stock has experienced three consecutive trading limit increases, and it has issued a notice regarding abnormal stock trading fluctuations [4]. Group 3: Shareholder Issues - The controlling shareholder, Shanghai Guijiu Enterprise Development Co., Ltd., and its concerted parties have had a total of 216,740,245 shares judicially frozen, representing 64.80% of the company's total share capital [4].

Core Viewpoint - *ST Rock (600696) has announced a preliminary forecast indicating a significant decline in revenue and potential delisting due to financial issues in 2025 [2][4]. Financial Performance - The company expects its 2025 annual revenue to be below 300 million yuan, with total profit, net profit, or net profit after deducting non-recurring gains and losses expected to be negative [2]. - The 2024 financial report received a qualified opinion from the auditing firm, indicating major uncertainties regarding the company's ability to continue as a going concern [4]. Stock Market Implications - Due to the anticipated financial performance, the company's stock may face delisting under financial criteria as per the Shanghai Stock Exchange regulations [4]. - As of the report, *ST Rock's stock price has experienced three consecutive trading limit increases, despite the looming delisting risk [4]. Shareholder Issues - The controlling shareholder, Shanghai Guijiu Enterprise Development Co., Ltd., and its concerted parties have had a total of 216,740,245 shares judicially frozen, representing 64.80% of the company's total share capital [4]. Legal Matters - The actual controller of the company, Mr. Han Yao, has been subjected to criminal coercive measures due to the illegal fundraising activities of Haiyin Wealth Management Co., Ltd. [5].

Core Viewpoint - *ST Rock (600696) is facing significant financial challenges, with projected revenue for 2025 expected to be below 300 million yuan, leading to potential delisting risks due to financial criteria [2][4]. Financial Performance - The company anticipates a total revenue of less than 300 million yuan for the fiscal year 2025, with both total profit and net profit expected to be negative [2]. - The 2024 financial report received a qualified audit opinion from Zhongxing Caiguanghua Accounting Firm, indicating major uncertainties regarding the company's ability to continue as a going concern [4]. Delisting Risks - If the 2025 financial report receives a qualified opinion, or if there are negative opinions on internal controls, the company may face delisting under the Shanghai Stock Exchange rules [4]. - The stock has already experienced three consecutive trading halts, indicating volatility and investor concern [4]. Shareholder Issues - The controlling shareholder, Shanghai Guijiu Enterprise Development Co., Ltd., and its concerted parties have had 64.80% of their shares (216,740,245 shares) judicially frozen [4]. - The actual controller, Mr. Han Xiao, is under criminal coercive measures due to an investigation related to illegal fundraising by Haiyin Wealth Management Co., Ltd. [4].

Core Viewpoint - A total of 178 companies in the Shanghai and Shenzhen stock markets are at risk of triggering financial delisting indicators based on their Q3 reports, indicating a potential for delisting risk warnings if their Q4 performance does not improve [2][3]. Financial Indicators - Among the 178 companies, 145 are from the main board with "net profit loss + revenue below 300 million" criteria, while 33 are from the Sci-Tech Innovation Board and Growth Enterprise Market with "net profit loss + revenue below 100 million" [3]. - Specific companies like Shahe Co., China High-Tech, and Renzhi Co. reported revenues of 20.86 million, 62.97 million, and 68.54 million respectively, indicating significant shortfalls from the 300 million revenue threshold [3][4]. Company Actions - Companies are taking various measures to "self-rescue," including mergers, asset sales, and restructuring efforts to improve their financial standings [6]. - Shahe Co. is planning a major asset restructuring to acquire 70% of Shenzhen Jinghua Display Electronics Co., which has shown strong profitability in recent years [6]. - ST Lingda is attempting to undergo bankruptcy restructuring, having reported a revenue of 89.09 million, which is close to the 100 million target for the year [7]. Regulatory Environment - The new delisting regulations stipulate that companies failing to meet specific financial criteria will face delisting risk warnings, with the potential for mandatory delisting if conditions do not improve [2][4]. - The regulatory environment has become stricter, prompting companies to adopt more standardized approaches to maintain their listings [2]. Market Trends - As companies approach the end of the fiscal year, there is an increased urgency to secure large contracts, as seen with Hopu Co. signing a 520 million contract for energy storage systems [8][9].

Core Viewpoint - The company faces significant risks of being delisted due to allegations of financial misconduct, including inflated revenue and profits from 2020 to 2023, as identified by the China Securities Regulatory Commission (CSRC) [11][14][15]. Financial Performance - For the first nine months of 2025, the company's aesthetic biomedical business generated revenue of 303.61 million yuan, an increase of 52.78% compared to the previous year [21]. - The pharmaceutical business reported revenue of 468.06 million yuan, a decrease of 55.79% year-on-year, with the pharmaceutical manufacturing segment contributing 345.22 million yuan and the pharmaceutical commerce segment 122.84 million yuan [21]. Regulatory Issues - The company received a notice from the CSRC on July 13, 2025, indicating potential administrative penalties for falsely reporting financial data, which could lead to mandatory delisting [12][14]. - The company has been under investigation since February 26, 2025, for suspected violations of information disclosure laws [13]. Shareholder and Stock Status - The company's controlling shareholder's shares are fully pledged or subject to judicial restrictions, raising concerns about liquidity and control [18]. - The stock has been placed under risk warning due to the ongoing investigation and potential delisting risks [12][16]. Other Operational Risks - The company reported a net loss of 87.47 million yuan for the first three quarters of 2025, a decline of 294.03% compared to the same period last year [18]. - There are unresolved issues regarding non-operational fund occupation by related parties, with significant amounts reported as of the end of 2023 [17].

Core Viewpoint - The company, Yuancheng Environment Co., Ltd., is under investigation by the China Securities Regulatory Commission (CSRC) for suspected false disclosures in financial reports, which poses significant risks of forced delisting due to major violations [1][3]. Financial Risks - For the first half of 2025, the company reported revenue of 82.34 million yuan and a net loss attributable to shareholders of 126.80 million yuan, which may lead to delisting risks if the annual report does not meet the requirements set by the Shanghai Stock Exchange [2]. - The company is subject to a risk warning due to its financial performance, and if the 2025 annual report does not meet the delisting criteria, the company's stock may be terminated from listing [2]. Operational Status - As of the announcement date, the company's business activities are reported to be operating normally, and the CSRC's investigation is ongoing without any conclusive findings yet [3]. - The company and its controlling shareholder are cooperating with the CSRC's investigation and will provide monthly updates on the progress of the investigation as required by the stock listing rules [3]. Risk Warnings - The company faces uncertainties regarding its ability to continue operations and liquidity risks, with multiple bank accounts frozen, totaling a significant amount in restricted funds [2].

Core Viewpoint - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. faces significant risks of forced delisting due to major violations and financial issues, including false reporting of revenue and profits from 2020 to 2023 [4]. Group 1: Major Violation Delisting Risk - The company received an administrative penalty notice from the China Securities Regulatory Commission (CSRC) for falsely inflating operating income, costs, and profits, which may lead to forced delisting [4]. - The company’s stock has been under risk warning since July 14, 2025, due to the potential for major violations leading to termination of listing [1][4]. Group 2: Financial Delisting Risk - The 2024 financial report received a disclaimer of opinion from the auditing firm, triggering financial delisting risks under the Shanghai Stock Exchange rules [1][2]. - The company is currently under risk warning due to financial issues, including the inability to express an opinion on internal controls [2]. Group 3: Other Risk Warnings - The company is facing additional risk warnings due to non-operational fund occupation by related parties, which violates stock exchange regulations [2]. - The company has also encountered operational risks, including a contract termination with a medical product distributor, affecting sales [2]. Group 4: Investor Advisory - The company urges investors to be cautious and rational in their investment decisions, especially given the recent abnormal stock price fluctuations that do not align with deteriorating fundamentals [4].